Actively Recruiting
Observational Study of Commercial CAR T Therapy in Older Patients With Blood Cancers Including Geriatric and Neurocognitive Assessments
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-04-07
154
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating how older patients respond to CAR-T cell therapy and how this treatment affects their quality of life. This observational study focuses on adults aged 60 and older with relapsed refractory lymphoid malignancies or plasma cell disorders. It aims to understand quality of life changes without altering the standard treatment participants receive. Participants include older patients undergoing CAR T therapy for various blood cancers, such as high-grade B-cell lymphoma, other lymphoid malignancies, and plasma cell disorders. The study involves detailed assessments including geriatric evaluations, neurocognitive testing, and quality of life questionnaires before and after treatment. The follow-up period for participants is one year. During the study, participants will complete various tests such as activities of daily living, cognitive assessments, depression screening, social support questionnaires, and blood draws. The main outcome measured is the number of participants who complete all required assessment visits within one year before disease progression or death. This study helps researchers monitor the patient experience and treatment impact over time.
CONDITIONS
Brief Title
Study of CAR-T Therapy in Older Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Be 60 years old or older
- Have a confirmed diagnosis of relapsed refractory lymphoid malignancy or plasma cell disorder and be receiving a commercial CAR T-cell product
- Be able to speak and understand English (for some cohorts)
- Have a MoCA score below 26 before CAR T treatment (for specific cohort)
You will not qualify if you...
- Have received any prior commercial or investigational CAR T therapy
- Have a current diagnosis of major psychiatric disorders such as major depression, bipolar disorder, or schizophrenia (for some cohorts)
- Have a history of neurological disorder, neurodegenerative disease, or traumatic brain injury with loss of consciousness longer than 60 minutes (for some cohorts)
- Have current or past substance abuse issues (for some cohorts)
- Have a history of central nervous system disease (for specific cohort)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 1 month prior to treatment
Participants undergo comprehensive geriatric assessment, neurocognitive testing, and quality of life evaluation prior to CAR T therapy.
1 to 2 visits depending on assessments
Duration - Up to 1 year following CAR T therapy
Participants who undergo CAR T therapy are observed with ongoing assessments including geriatric and neurocognitive evaluations, quality of life measures, and blood draws.
Regular visits for up to 12 months
Trial Site Locations
Total: 1 location
1
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Actively Recruiting
Research Team
R
Richard Lin, MD, PhD
S
Sergio Giralt, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here